ABSTRACT Aims and Objectives: To find out if ischemia modified albumin can be a novel
marker in ischemic heart disease. Materials and methods: Retrospective chart-review of …

Existing biochemical markers are not suitable for assessing early myocardial ischemia
particularly in first 2-6 hours of ischemia ie before setting in of irreparable myocardial …

Ischemia modified albumin (IMA) is a relatively new marker for evaluating patients with
cardiac ischemia. Data are emerging on its potential role in non-cardiac ischemic events. In …

Objective To evaluate the diagnostic efficacy of ischemia modified albumin (IMA) and its
correlation with lipid profile, oxidative stress in acute myocardial infarct (AMI) patients …

Early identification of patients with acute myocardial infarction is of prime importance due to
the associated very high mortality. Only 22% of the patients presenting at emergency …

Background: Ischemia-modified albumin (IMA) has been suggested as a marker of cardiac
ischemia. Little, however, is known about its capacity to predict short-term serious cardiac …

The diagnosis of cardiac ischemia remains a challenge in contemporary emergency
medicine. A blood-borne biomarker is an attractive alternative to cardiac imaging or stress …

Background: Ischemia-modified albumin has been proposed as a useful rule-out marker for
the diagnosis of acute coronary syndrome in the emergency department. Objective: To …

Myocardial ischemia produces free radicals that catalyze a series of oxidative reactions that
damage healthy tissues. The N-terminal sequence of albumin is one of the proteins modified …

Difficulty in establishing a diagnosis of acute coronary syndrome (ACS) in the clinical setting
has led researchers to investigate novel markers that show increased blood levels before …